Financials Rani Therapeutics Holdings, Inc.
Equities
RANI
US7530181004
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.68 USD | +1.83% | -5.52% | +101.20% |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 322.3 | 145.8 | 85.92 | 175.7 | - | - |
Enterprise Value (EV) 1 | 322.3 | 77.02 | 85.92 | 175.6 | 225.7 | 284.4 |
P/E ratio | -38 x | -4.61 x | -2.5 x | -7.95 x | -9.21 x | -9.97 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 119 x | - | - | - | - | 12.3 x |
EV / Revenue | 119 x | - | - | - | - | 19.9 x |
EV / EBITDA | -6.31 x | -1.22 x | -1.32 x | -2.88 x | -3.43 x | -6.27 x |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | 7.91 x | - | - | - | - |
Nbr of stocks (in thousands) | 19,712 | 24,720 | 25,880 | 26,299 | - | - |
Reference price 2 | 16.35 | 5.900 | 3.320 | 6.680 | 6.680 | 6.680 |
Announcement Date | 3/31/22 | 3/22/23 | 3/20/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | 2.717 | - | - | - | - | 14.3 |
EBITDA 1 | - | -51.1 | -62.9 | -65.28 | -60.87 | -65.73 | -45.35 |
EBIT 1 | - | -51.6 | -63.45 | -66.1 | -54.87 | -60.94 | -56.02 |
Operating Margin | - | -1,899.12% | - | - | - | - | -391.77% |
Earnings before Tax (EBT) 1 | - | -53.05 | -63.27 | -67.88 | -54.53 | -61.65 | -64.22 |
Net income 1 | -16.7 | -8.331 | -30.59 | -33.97 | -29.13 | -32.69 | -31.63 |
Net margin | - | -306.62% | - | - | - | - | -221.23% |
EPS 2 | -0.3600 | -0.4300 | -1.280 | -1.330 | -0.8400 | -0.7250 | -0.6700 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 4/27/21 | 3/31/22 | 3/22/23 | 3/20/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | -27.66 | -13.25 | -13.67 | -15.72 | -16.2 | -17.31 | -16.33 | -18.1 | -17.64 | -13.21 | -14.18 | -15.69 | -15.55 | -15.45 |
EBIT 1 | -27.78 | -13.36 | -13.78 | -15.85 | -16.34 | -17.48 | -16.52 | -18.29 | -17.86 | -13.43 | -13.44 | -13.96 | -14.13 | -14.87 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -28.66 | -13.34 | -13.76 | -15.81 | -16.32 | -17.38 | -16.83 | -18.66 | -18.33 | -14.06 | -13.87 | -13.81 | -14.04 | -15.54 |
Net income 1 | -3.142 | -5.189 | -6.223 | -7.624 | -7.955 | -8.786 | -8.372 | -9.303 | -9.197 | -7.098 | -6.941 | -7.016 | -7.416 | -8.116 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.1600 | -0.2700 | -0.2900 | -0.3100 | -0.3300 | -0.3500 | -0.3300 | -0.3700 | -0.3600 | -0.2700 | -0.2033 | -0.1900 | -0.1900 | -0.1733 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/16/21 | 3/31/22 | 5/11/22 | 8/10/22 | 11/10/22 | 3/22/23 | 5/10/23 | 8/11/23 | 11/8/23 | 3/20/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | 50 | 109 |
Net Cash position 1 | - | - | 68.8 | - | 0.12 | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | -0.7607 x | -2.398 x |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | -72.6% | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | 0.7500 | - | - | - | - |
Cash Flow per Share | - | -1.650 | -1.950 | - | - | - | - |
Capex | - | 0.51 | 1.62 | - | - | - | - |
Capex / Sales | - | 18.62% | - | - | - | - | - |
Announcement Date | 4/27/21 | 3/31/22 | 3/22/23 | 3/20/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+101.20% | 176M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RANI Stock
- Financials Rani Therapeutics Holdings, Inc.